EP2 receptor Inhibitors
1 drugsAbout EP2 receptor
The EP2 receptor, also known as prostaglandin E2 receptor 2, is a GPCR mediating PGE2 effects in various physiological processes.
While the EP2 receptor's involvement in diverse pathways makes it a compelling target, there is currently no genetic evidence directly linking it to specific diseases.
OMLONTI is the only FDA-approved drug targeting EP2, developed by OCUVEX THERAP as a small molecule for other therapeutic areas.
Top EP2 receptor Drugs
OCUVEX THERAP is the only company with an approved drug targeting EP2.
Low competition suggests an opportunity for new entrants in the EP2 receptor market.
EP2 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets EP2 receptor, using small molecule modality.
Exploring alternative modalities like antibodies could create differentiation in the EP2 space.
EP2 receptor Drug Approval Timeline (2022 - 2022)
The first and most recent drug approval for EP2 was OMLONTI in 2022.
Recent approval suggests renewed interest, but further approvals are needed to confirm trajectory.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Full summary • All drugs • Genetic evidence • Trials • Timeline